Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumor
This is a Phase 1, open-label, multicenter, dose-escalation, safety, tolerability, pharmacokinetic and pharmacodynamic study with cohort expansion at the RP2D to evaluate safety and anti- tumor activity of Q702 administered orally.
Solid Tumor|Advanced Cancer|Metastatic Cancer
DRUG: Q702
Maximum tolerated dose (MTD), the dose limiting toxicities (DLT) and the safety profile of Q702, 28 days of cycle 1
Change in the area under curve (AUC) of Q702, Cycle 1, Days 1,2,8,15,21,22; Cycle 2, Days 1,8,15,22|Change in the maximum plasma concentration (Cmax) of Q702, Cycle 1, Days 1,2,8,15,21,22; Cycle 2, Days 1,8,15,22|Change in the time of maximum plasma concentration (Tmax) of Q702, Cycle 1, Days 1,2,8,15,21,22; Cycle 2, Days 1,8,15,22|Tumor response using RECIST version 1.1 throughout study, Baseline up to approximately 2 years
This is a Phase 1, open-label, multicenter, dose-escalation, safety, tolerability, pharmacokinetic and pharmacodynamic study with cohort expansion at the RP2D to evaluate safety and anti- tumor activity of Q702 administered orally.